AngioDynamics, Inc.
ANGONext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for ANGO. That does not mean none is planned.
Get an email about ANGO's next catalysts
Track AngioDynamics (ANGO) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
ANGO Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.11 | FQ end Nov/2026 | Call: tbd
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Modified FOLFIRINOX Regimen | Phase 3 | Stage III Pancreatic Cancer | - | - |
IP-001 | Phase 2 | Colorectal Cancer | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in AngioDynamics, Inc.'s drug pipeline?β
CatalystAlert tracks 2 drug candidates in AngioDynamics, Inc.'s (ANGO) pipeline across Phase 3, Phase 2. Its lead program is Modified FOLFIRINOX Regimen (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is AngioDynamics, Inc.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for AngioDynamics, Inc. (ANGO) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track ANGO biotech catalysts?β
Add ANGO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow AngioDynamics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
